Modulation of the endocannabinoid system in viable and non-viable first trimester pregnancies by pregnancy-related hormones

Reproductive Biology and Endocrinology

Justin C Konje¹  Patricia MW Lam¹  Mark Finney¹  Anthony H Taylor¹ 

[1] Endocannabinoid Research Group, Reproductive Sciences Section, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK

关键词: β-hCG;    progesterone;    PAPP-A;    miscarriage;    endocannabinoid;    cannabinoid receptor;    Anandamide;   

Others  :  1151301
DOI  :  10.1186/1477-7827-9-152

 received in 2011-05-26, accepted in 2011-11-29,  发布年份 2011

【 摘 要 】

Background

In early pregnancy, increased plasma levels of the endocannabinoid anandamide (AEA) are associated with miscarriage through mechanisms that might affect the developing placenta or maternal decidua.

Methods

In this study, we compare AEA levels in failed and viable pregnancies with the levels of the trophoblastic hormones (beta-human chorionic gonadotrophin (beta-hCG), progesterone (P4) and (pregnancy-associated placental protein-A (PAPP-A)) essential for early pregnancy success and relate that to the expression of the cannabinoid receptors and enzymes that modulate AEA levels.

Results

The median plasma AEA level in non-viable pregnancies (1.48 nM; n = 20) was higher than in viable pregnancies (1.21 nM; n = 25; P = 0.013), as were progesterone and beta-hCG levels (41.0 vs 51.5 ng/mL; P = 0.052 for P4 and 28,650 vs 6,560 mIU/L; P = 0.144 for beta-hCG, respectively, but were not statistically significant). Serum PAPP-A levels in the viable group were approximately 6.8 times lower than those in the non-viable group (1.82 vs 12.25 mg/L; P = 0.071), but again these differences were statistically insignificant. In the spontaneous miscarriage group, significant correlations between P4 and beta-hCG, P4 and PAPP-A and AEA and PAPP-A levels were observed. Simultaneously, immunohistochemical distributions of the two main cannabinoid receptors and the AEA-modifying enzymes, fatty acid amide hydrolase (FAAH) and N-acylphosphatidylethanolamine-phospholipase D (NAPE-PLD), changed within both the decidua and trophoblast.

Conclusions

The association of higher AEA levels with early pregnancy failure and with beta-hCG and PAPP-A, but not with progesterone concentrations suggest that plasma AEA levels and pregnancy failure are linked via a mechanism that may involve trophoblastic beta-hCG, and PAPP-A, but not, progesterone production. Although the trophoblast, decidua and embryo contain receptors for AEA, the main AEA target in early pregnancy failure remains unknown.

【 授权许可】

   
2011 Taylor et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Elson J, Salim R, Tailor A, Banerjee S, Zosmer N, Jurkovic D: Prediction of early pregnancy viability in the absence of an ultrasonically detectable embryo. Ultrasound Obstet Gynecol 2003, 21(1):57-61.
• [2]Norwitz ER, Schust DJ, Fisher SJ: Implantation and the survival of early pregnancy. New Engl J Med 2001, 345(19):1400-1408.
• [3]Barnhart K, Sammel MD, Chung K, Zhou L, Hummel AC, Guo W: Decline of serum human chorionic gonadotropin and spontaneous complete abortion: defining the normal curve. Obstet Gynecol 2004, 104(5 Pt 1):975-981.
• [4]Ellish NJ, Saboda K, O'Connor J, Nasca PC, Stanek EJ, Boyle C: A prospective study of early pregnancy loss. Hum Reprod 1996, 11(2):406-412.
• [5]Elson J, Tailor A, Salim R, Hillaby K, Dew T, Jurkovic D: Expectant management of miscarriage--prediction of outcome using ultrasound and novel biochemical markers. Hum Reprod 2005, 20(8):2330-2333.
• [6]Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH: First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. Brit J Obstet Gynaecol 2000, 107(10):1265-1270.
• [7]Al-Azemi M, Ledger WL, Diejomaoh M, Mousa M, Makhseed M, Omu A: Measurement of inhibin A and inhibin pro-alphaC in early human pregnancy and their role in the prediction of pregnancy outcome in patients with recurrent pregnancy loss. Fertil Steril 2003, 80(6):1473-1479.
• [8]Tong S, Marjono B, Mulvey S, Wallace EM: Low levels of pregnancy-associated plasma protein-A in asymptomatic women destined for miscarriage. Fertil Steril 2004, 82(5):1468-1470.
• [9]Yovich JL, Willcox DL, Grudzinskas JG, Bolton AE: The prognostic value of HCG, PAPP-A, oestradiol-17 beta and progesterone in early human pregnancy. Aust N Z J Obstet Gynaecol 1986, 26(1):59-64.
• [10]Maccarrone M, Finazzi-Agro A: Anandamide hydrolase: a guardian angel of human reproduction? Trends Pharmacol Sci 2004, 25(7):353-357.
• [11]Wang H, Xie H, Guo Y, Zhang H, Takahashi T, Kingsley PJ, Marnett LJ, Das SK, Cravatt BF, Dey SK: Fatty acid amide hydrolase deficiency limits early pregnancy events.[see comment]. J Clin Invest 2006, 116(8):2122-2131.
• [12]El-Talatini MR, Taylor AH, Konje JC: Fluctuation in anandamide levels from ovulation to early pregnancy in in-vitro fertilization-embryo transfer women, and its hormonal regulation. Hum Reprod 2009, 24(8):1989-1998.
• [13]Maccarrone M, Bisogno T, Valensise H, Lazzarin N, Fezza F, Manna C, Di Marzo V, Finazzi-Agro A: Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol Hum Reprod 2002, 8(2):188-195.
• [14]Karasu T, Marczylo TH, Maccarrone M, Konje JC: The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. Hum Reprod Update 2011, 17(3):347-361.
• [15]Taylor AH, Amoako AA, Bambang K, Karasu T, Gebeh A, Lam PM, Marzcylo TH, Konje JC: Endocannabinoids and pregnancy. Clin Chim Acta 2010, 411(13-14):921-930.
• [16]Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor.[see comment]. Science 1992, 258(5090):1946-1949.
• [17]Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34(5):605-613.
• [18]Paria BC, Reese J, Das SK, Dey SK: Deciphering the cross-talk of implantation: advances and challenges. Science 2002, 296(5576):2185-2188.
• [19]Guo Y, Wang H, Okamoto Y, Ueda N, Kingsley PJ, Marnett LJ, Schmid HHO, Das SK, Dey SK: N-Acylphosphatidylethanolamine-hydrolyzing phospholipase D is an important determinant of uterine anandamide levels during implantation. J Biol Chem 2005, 280(25):23429-23432.
• [20]Schmid PC, Paria BC, Krebsbach RJ, Schmid HH, Dey SK: Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci USA 1997, 94(8):4188-4192.
• [21]Boldrup L, Wilson SJ, Barbier AJ, Fowler CJ: A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J Biochem Biophys Methods 2004, 60(2):171-177.
• [22]Cravatt BF, Lichtman AH: The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 2002, 121(1-2):135-148.
• [23]Deutsch DG, Glaser ST, Howell JM, Kunz JS, Puffenbarger RA, Hillard CJ, Abumrad N: The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J Biol Chem 2001, 276(10):6967-6973.
• [24]Deutsch DG, Ueda N, Yamamoto S: The fatty acid amide hydrolase (FAAH).[erratum appears in Prostaglandins Leukot Essent Fatty Acids.2003 Jan;68(1):69.]. Prostaglandins Leukot Essent Fatty Acids 2002, 66(2-3):201-210.
• [25]Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegenthart JF, Agro AF: Anandamide hydrolysis by human cells in culture and brain. J Biol Chem 1998, 273(48):32332-32339.
• [26]McKinney MK, Cravatt BF: Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005, 74:411-432.
• [27]Habayeb OMH, Taylor AH, Finney M, Evans MD, Konje JC: Plasma anandamide concentrations predict the outcome of pregnancy in women presenting with threatened miscarriage. J Am Med Assoc 2008, 299:1135-1136.
• [28]Laursen LS, Overgaard MT, Soe R, Boldt HB, Sottrup-Jensen L, Giudice LC, Conover CA, Oxvig C: Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: implications for the mechanism of IGFBP-4 proteolysis by PAPP-A. FEBS Letts 2001, 504(1-2):36-40.
• [29]Maccarrone M, Bari M, Di Rienzo M, Finazzi-Agro A, Rossi A: Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin. J Biol Chem 2003, 278(35):32726-32732.
• [30]Kenney SP, Kekuda R, Prasad PD, Leibach FH, Devoe LD, Ganapathy V: Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. Am J Obstet Gynecol 1999, 181:491-497.
• [31]Taylor AH, Abbas MS, Habiba MA, Konje JC: Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human uterus through the menstrual cycle. Histochem Cell Biol 2010, 133:557-565.
• [32]Habayeb OM, Taylor AH, Evans MD, Cooke MS, Taylor DJ, Bell SC, Konje JC: Plasma levels of the endocannabinoid anandamide in women--a potential role in pregnancy maintenance and labor? J Clin Endocrinol Metab 2004, 89(11):5482-5487.
• [33]Lam PM, Marczylo TH, El-Talatini M, Finney M, Nallendran V, Taylor AH, Konje JC: Ultra performance liquid chromatography tandem mass spectrometry method for the measurement of anandamide in human plasma. Anal Biochem 2008, 380(2):195-201.
• [34]Derecskei K, Moldvay J, Bogos K, Timar J: Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx in paraffin-embedded cancer tissues. Pathol Oncol Res 2006, 12(4):243-246.
• [35]Habayeb OM, Taylor AH, Bell SC, Taylor DJ, Konje JC: Expression of the endocannabinoid system in human first trimester placenta and its role in trophoblast proliferation. Endocrinology 2008, 149(10):5052-5060.
• [36]El-Talatini MR, Taylor AH, Elson JC, Brown L, Davidson AC, Konje JC: Localisation and function of the endocannabinoid system in the human ovary. PLoS ONE 2009, 4(2):e4579.
• [37]Hamilton PW: Designing a morphometric study. In Quantitative Clinical Pathology. Edited by Allen DC. Oxford: Blackwell Science; 1995:311-315.
• [38]GraphPad Prism [http://www.graphpad.com/prism/Prism.htm] webcite
• [39]Chamley LW, Bhalla A, Stone PR, Liddell H, O'Carroll S, Kearn C, Glass M: Nuclear localisation of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent miscarriage. Placenta 2008, 29(11):970-975.
• [40]Helliwell RJ, Chamley LW, Blake-Palmer K, Mitchell MD, Wu J, Kearn CS, Glass M: Characterization of the endocannabinoid system in early human pregnancy. J Clin Endocrinol Metab 2004, 89(10):5168-5174.
• [41]Park B, Gibbons HM, Mitchell MD, Glass M: Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta 2003, 24:473-478.
• [42]El-Talatini MR, Taylor AH, Konje JC: The pattern of anandamide expression throughout the menstrual cycle and its hormonal modulation. Fertil Steril 2010, 93:1989-1996.
• [43]Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agro A: Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 2000, 355:1326-1293.
• [44]Paria BC, Deutsch DD, Dey SK: The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Mol Reprod Dev 1996, 45:183-192.
• [45]Lazzarin N, Valensise H, Bari M, Ubaldi F, Battista N, Finazzi-Agro A, Maccarrone M: Fluctuations of fatty acid amide hydrolase and anandamide levels during the human ovulatory cycle. Gynecol Endocrinol 2004, 18:212-218.
• [46]Nulsen JC, Peluso JJ: Regulation of ovarian steroid production. Infertil Reprod Med Clinics North Am 1992, 3:44-55.
• [47]Ioannidis G, Sacks G, Reddy N, Seyani L, Margara R, Lavery S, Trew G: Day 14 maternal serum progesterone levels predict pregnancy outcome in IVF/ICSI treatment cycles: a prospective study. Hum Reprod 2005, 20(3):741-746.
• [48]Condous G, Lu C, Van Huffel SV, Timmerman D, Bourne T: Human chorionic gonadotrophin and progesterone levels in pregnancies of unknown location. Int J Gynaecol Obstet 2004, 86(3):351-357.
• [49]Gevaert O, De Smet F, Kirk E, Van Calster B, Bourne T, Van Huffel S, Moreau Y, Timmerman D, De Moor B, Condous G: Predicting the outcome of pregnancies of unknown location: Bayesian networks with expert prior information compared to logistic regression. Hum Reprod 2006, 21(7):1824-1831.
• [50]Potdar N, Konje JC: The endocrinological basis of recurrent miscarriages. Curr Opin Obstet Gynecol 2005, 17(4):424-428.
• [51]Chetty M, Elson J: Biochemistry in the diagnosis and management of abnormal early pregnancy. Clin Obstet Gynecol 2007, 50(1):55-66.
• [52]Schindler AE: Endocrinology of pregnancy: consequences for the diagnosis and treatment of pregnancy disorders. J Steroid Biochem Mol Biol 2005, 97(5):386-388.
• [53]Cuckle HS, Sehmi IK, Jones RG, Mason G: Low maternal serum PAPP-A and fetal viability. Prenat Diagn 1999, 19(8):788-790.
• [54]Ruge S, Pedersen JF, Sorensen S, Lange AP: Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability? Acta Obstet Gynecol Scand 1990, 69(7-8):589-595.
• [55]Westergaard JG, Sinosich MJ, Bugge M, Madsen LT, Teisner B, Grudzinskas JG: Pregnancy-associated plasma protein A in the prediction of early pregnancy failure. Am J Obstet Gynecol 1983, 145(1):67-69.
• [56]Boldt HB, Conover CA: Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm IGF Res 2007, 17(1):10-18.
• [57]Acone G, Trabucco E, Colacurci N, Cobellis L, Mackie K, Meccariello R, Cacciola G, Chioccarelli T, Fasano S, Pierantoni R, et al.: Low type I cannabinoid receptor levels characterize placental villous in labouring delivery. Placenta 2009, 30(2):203-205.
• [58]Kaczocha M, Glaser ST, Deutsch DG: Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci USA 2009, 106(15):6375-6380.
• [59]Maccarrone M, Dainese E, Oddi S: Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci 2010, 35(11):601-608.
• [60]Fonseca BM, Correia-da-Silva G, Taylor AH, Konje JC, Bell SC, Teixeira NA: Spatio-temporal expression patterns of anandamide-binding receptors in rat implantation sites: evidence for a role of the endocannabinoid system during the period of placental development. Reprod Biol Endocrinol 2009, 7:121. BioMed Central Full Text
• [61]Fonseca BM, Correia-da-Silva G, Taylor AH, Lam PM, Marczylo TH, Konje JC, Bell SC, Teixeira NA: N-acylethanolamine levels and expression of their metabolizing enzymes during pregnancy. Endocrinology 2010, 151(8):3965-3974.
• [62]Trabucco E, Acone G, Marenna A, Pierantoni R, Cacciola G, Chioccarelli T, Mackie K, Fasano S, Colacurci N, Meccariello R, et al.: Endocannabinoid system in first trimester placenta: low FAAH and high CB1 expression characterize spontaneous miscarriage. Placenta 2009, 30(6):516-522.
• [63]Khare M, Taylor AH, Konje JC, Bell SC: Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod 2006, 12(5):321-333.
• [64]Fonesca BM, Correia-da-Silva G, Teixeira NA: Anandamide-induced cell death: dual effects in primary rat decidual cell cultures. Placenta 2009, 30(8):686-692.